Submission and guidelines

How to Submit an Abstract

Delegates, who would like to present their work at the congress, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee. ISFP Members and Non-Members are invited to submit abstracts.

There are no fees to submit an abstract. Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISFP 2022 Congress-ExOrdo website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

The submitter will be required to login with your Member login credentials or create a user account in order to submit an abstract. Once logged in you will be able to submit your abstract. Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (extended to April 30th, 2022).

The submitted/draft abstracts cannot be edited after the submission deadline. Only abstracts that have been submitted properly will be considered for the congress. Any technical questions regarding the submission website should be sent to ISFP.PA.2022@gmail.com


Proposed Topics

  • Fibrinogen, Fibrin and Factor XIII Interactions
  • Serpins
  • Cell-mediated PA & Fibrinolysis and Structural/Functional studies (preclinical)
  • Novel Therapeutics
  • Thrombolytic therapy (clinical)
  • PA & Neurovascular System & Blood Brain Barrier
  • PA Infection, Immunity and Cancer
  • PA & Biomarkers
  • Other functions of fibrinolytics
  • Proteases, bleeding and Anticoagulation
  • Proteases, platelets and VWF
  • Proteases and Contact Phase
  • Imaging thrombosis and the PA system


Preparing an Abstract for Submission

Authors and Co-Authors

The first/presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

The presenting author of the abstract must be registered for the meeting.

The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.

A maximum of 20 authors is permitted on each abstract.

Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

Conflict of Interest

It is the intent of the ISFP to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting/presenting author of an abstract is required to declare any potential conflicts of interest for the presenting author during abstract submission.

Abstract Body

For standardization, the acceptable length of the abstract is a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

Background

Aims

Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study.

Results: Which should contain objective data to answer the scientific question(s).

Conclusions: Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

Other Items for Consideration:

In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the abstract text.

Abbreviations should be defined.

If off-label use of drugs was involved in the study, please state this clearly.